DNA-Encoded Libraries: Platforms and Services Market- Roots Analysis

1. DNA-Encoded Libraries: Platforms and Services Market Roots Analysis https://www.rootsanalysis.com/ https://www.rootsanalysis.com/reports/view_document/dna-encoded-libraries/288.html

2. Example Insights • Presently, nearly 30 DNA-encoded libraries are available to various pharmaceutical companies for the purpose of drug discovery. Majority of the DNA-encoded libraries are designed to identify leads against protein pump inhibitors which are otherwise difficult to screen using traditional libraries. However, with respect to the type of pharmacological leads, over 20 libraries are designed for discovery of small molecules, followed by macrocycles. • The market is highly fragmented, featuring a mix of small-sized companies (less than 50 employees, 48%), mid-sized companies (more than 51 employees, 20%), large companies (more than 500 employees, 8%) and very large companies (more than 5,000 employees, 24%) that offer DNA-encoded libraries. Notable examples of well-established players include (in alphabetical order, no selection criteria), Amgen (through acquisition of Nuevolution), ETH Zurich and GSK (through acquisition of Praecis Pharmaceuticals). • Although efforts for the development of DNA-encoded libraries have been undertaken by service providers based across the globe, majority of the players (48%) are headquartered in Europe. 40% of such companies are based in North America, while the remaining operate out of the Asia Pacific region and rest of the world.

3. Overview The process of drug development, beginning from the discovery of a molecule to its commercial launch, takes around 10-15 years and capital investments worth USD 4-10 billion. It is a well-known fact that only a small proportion of molecules, which are selected for further investigation during the initial stages of research, are actually translated into product candidates. Given the complexities involved in the drug discovery process, the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector has steadily increased over time. Specifically, in 2019, the R&D spending was estimated to be around USD 182 billion; over 16,000 drug molecules were reportedly evaluated during the year. The industry is presently under tremendous pressure not only to identify ways to mitigate the risks of failure of drug discovery programs but also to meet the expectations of a growing patient population. DNA-encoded libraries (also known as DELs), owing to their advantages (such as library size, cost and equipment needs) over high-throughput screening, have demonstrated to be a sophisticated combinatorial drug discovery tool for synthesis and screening of large collections of small molecule compounds. Interestingly, DNA-encoded libraries encompassing as high as 40 trillion different molecules have been developed, enabling screening, hit identification and discovery of pharmacological leads (including macrocycles, natural products and small molecules) against undruggable and unique targets using a single library and accelerating the process of drug development. Moreover, introduction of automated screening of small organic ligands using DNA-encoded chemical libraries has enabled identification of potential lead molecules within a time duration of 10 days.

5. Scope of the Report The “DNA-Encoded Libraries: Platforms and Services Market” report features an extensive study of the current landscape and the untapped opportunities these DNA-encoded likely to bring in the field of drug discovery. In addition to other elements, the report includes: • An overview of the current market landscape of DNA-encoded libraries, featuring details on the type of pharmacological lead (macrocycles, natural products, peptides and small molecules), type of services offered, library size, method of library synthesis, type of therapeutic target and type of therapeutic area. • An overview of the landscape of DNA-encoded library developers and analysis based on parameters, such as year of establishment, company size, type of service offered (screening service / hit identification, hit optimization / validation, custom library design / synthesis, in-house / out-source drug development and DNA-encoded library kits) and geographical location. • A detailed analysis of the partnerships related to DNA-encoded libraries, which have been established in the recent past, covering research collaborations, research and development agreements, licensing agreements, acquisitions, distribution agreements, service alliances, and other relevant agreements.

6. Chapter Outlines Chapter 2 is an executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the DNA-encoded libraries developers’ market and its evolution in the short-mid-term and long term. Chapter 3 provides an introduction to the process of drug discovery and development. In addition, the chapter focuses on the concept of DNA-encoded libraries with information on the evolution of these libraries, advantages over other conventional drug discovery methods and the challenges associated with the same. It also features a brief discussion on the opportunities and the likely future trends in this field. Chapter 4 provides a detailed overview of the current market landscape of DNA-encoded libraries, featuring information on type of pharmacological lead (macrocycles, natural products, peptides and small molecules), library size, method of library synthesis, type of therapeutic target and type of therapeutic area. In addition, the chapter provides an overview of DNA-encoded libraries developers and analysis based on parameters, such as year of establishment, company size, type of service offered (screening service / hit identification, hit optimization / validation, custom library design / synthesis, in-house / out-source drug development and DNA-encoded library kits) and geographical location.

7. More Reports - Roots Analysis • https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html • https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html • https://www.rootsanalysis.com/reports/view_document/dna-encoded-libraries/288.html • https://www.rootsanalysis.com/reports/view_document/prefilled-syringes-market/284.html • https://www.rootsanalysis.com/reports/view_document/med-dev-regulatory/282.html

8. Contact us • Address: A 430, Bestech Business Towers,, Sector 66, Sahibzada Ajit Singh Nagar, Punjab 160066 www.RootsAnalysis.com